Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
https://www.zacks.com/stock/news/2208792/mirati-mrtx-gets-eu-nod-for-krazati-in-kras-mutated-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208792
Jan 11, 2024 - Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
0
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718
Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
0
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
https://www.zacks.com/stock/news/2202691/bristol-myers-bmy-to-buy-cancer-drug-maker-rayzebio-for-4-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202691
Dec 27, 2023 - Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
0